Wolfe Research initiated coverage of Alpine Immune Sciences with an Outperform rating and $44 price target. The firm expects clinical data from povetacicept to meaningfully drive the stock. Wolfe added that the firm is bullish on a de-risked mechanism, and that Alpine has a more attractive clinical profile than its competitors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALPN:
- Alpine Immune Sciences Expands Investor Base with Warrant Exercises
- Biotech Alert: Searches spiking for these stocks today
- Alpine Immune Sciences price target raised to $33 from $30 at Oppenheimer
- Alpine Immune Sciences price target raised to $35 from $26 at Wedbush
- 3 Best Stocks to Buy Now, 12/25/2023, According to Top Analysts